Functional RNAi and CRISPR Screening and Drug Target & Biomarker Discovery
Cellecta Inc. provides custom and contract solutions for high-throughput genetic screening needs. Our research organization focuses primarily on developing and implementing flexible and scalable broad-based screening and analysis approaches that identify the mechanisms regulating biological processes to expedite the discovery and characterization of novel therapeutic targets and drugs. The unique capabilities of lentiviral, shRNA, and CRISPR technologies provide a platform that enables genome-wide functional screening and the identification and validation of genes involved in critical biological and pathological responses.
We’ll perform any or all steps, from RNAi and CRISPR screening to NGS to data analysis. Cellecta specializes in negative screens (i.e. viability or drop-out) to identify cancer drug targets.